TG Therapeutics Inc (NASDAQ: TGTX) has a higher price-to-earnings ratio of 148.73x compared to its average ratio, The 36-month beta value for TGTX is at 1.96. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TGTX is 142.87M, and currently, shorts hold a 16.59% of that float. The average trading volume for TGTX on July 03, 2025 was 2.48M shares.
TGTX) stock’s latest price update
TG Therapeutics Inc (NASDAQ: TGTX) has experienced a rise in its stock price by 2.51% compared to its previous closing price of $35.4. However, the company has seen a fall of -2.60% in its stock price over the last five trading days. seekingalpha.com reported 2025-06-25 that TG Therapeutics, Inc.’s BRIUMVI saw Q1 2025 revenue surge 137% YoY to $119.7M, driven by strong U.S. growth. A subcutaneous version of TGTX’s BRIUMVI is in phase 1 trials, with late-stage development planned for 2025, aiming to broaden patient reach and administration options. Azer-cel, an allogeneic off-the-shelf CD19 CAR-T, is in phase 1 for progressive MS, targeting a new MS market segment beyond relapsing MS.
TGTX’s Market Performance
TGTX’s stock has fallen by -2.60% in the past week, with a monthly rise of 1.51% and a quarterly drop of -3.87%. The volatility ratio for the week is 4.09% while the volatility levels for the last 30 days are 4.13% for TG Therapeutics Inc. The simple moving average for the past 20 days is -2.27% for TGTX’s stock, with a 11.24% simple moving average for the past 200 days.
Analysts’ Opinion of TGTX
Many brokerage firms have already submitted their reports for TGTX stocks, with TD Cowen repeating the rating for TGTX by listing it as a “Buy.” The predicted price for TGTX in the upcoming period, according to TD Cowen is $50 based on the research report published on October 29, 2024 of the previous year 2024.
Goldman, on the other hand, stated in their research note that they expect to see TGTX reach a price target of $12, previously predicting the price at $16. The rating they have provided for TGTX stocks is “Neutral” according to the report published on August 02nd, 2023.
Jefferies gave a rating of “Buy” to TGTX, setting the target price at $40 in the report published on June 26th of the previous year.
TGTX Trading at -2.10% from the 50-Day Moving Average
After a stumble in the market that brought TGTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.92% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TGTX starting from Echelard Yann, who sale 10,000 shares at the price of $36.94 back on Jun 13 ’25. After this action, Echelard Yann now owns 228,816 shares of TG Therapeutics Inc, valued at $369,400 using the latest closing price.
Stock Fundamentals for TGTX
Current profitability levels for the company are sitting at:
- 0.15 for the present operating margin
- 0.87 for the gross margin
The net margin for TG Therapeutics Inc stands at 0.1. The total capital return value is set at 0.12. Equity return is now at value 19.70, with 7.60 for asset returns.
Based on TG Therapeutics Inc (TGTX), the company’s capital structure generated 0.52 points at debt to capital in total, while cash flow to debt ratio is standing at -0.24. The debt to equity ratio resting at 1.07. The interest coverage ratio of the stock is 2.09.
Currently, EBITDA for the company is 49.9 million with net debt to EBITDA at 1.75. When we switch over and look at the enterprise to sales, we see a ratio of 15.23. The receivables turnover for the company is 2.03for trailing twelve months and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.02.
Conclusion
In conclusion, TG Therapeutics Inc (TGTX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
